Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway
IntroductionThe incidence of diabetes is rising annually, significantly impacting public health and imposing a substantial economic burden on society. Ophiopogonin D (Op D) exhibits certain hypoglycemic effects; however, its mechanisms remain unclear.Methodsβ-cell dedifferentiation, distinct from β-...
| Published in: | Frontiers in Pharmacology |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1563201/full |
| _version_ | 1849405227393875968 |
|---|---|
| author | Haoxiang Sun Ruixiang Tan Yongzhi Sun Yimeng Li Ying Xie Cheng Zhang Jianping Song Wei Zhu Jiuyao Zhou Changsheng Deng Manxue Mei |
| author_facet | Haoxiang Sun Ruixiang Tan Yongzhi Sun Yimeng Li Ying Xie Cheng Zhang Jianping Song Wei Zhu Jiuyao Zhou Changsheng Deng Manxue Mei |
| author_sort | Haoxiang Sun |
| collection | DOAJ |
| container_title | Frontiers in Pharmacology |
| description | IntroductionThe incidence of diabetes is rising annually, significantly impacting public health and imposing a substantial economic burden on society. Ophiopogonin D (Op D) exhibits certain hypoglycemic effects; however, its mechanisms remain unclear.Methodsβ-cell dedifferentiation, distinct from β-cell apoptosis, is a pathogenic mechanism we aim to explore regarding Op D’s regulatory effects. We established an animal model of β-cell dedifferentiation to assess Op D’s impact on glucose tolerance, blood glucose levels, and insulin secretion. We employed immunohistochemistry and immunofluorescence to analyze the expression levels of dedifferentiation-related proteins. Additionally, we created an in vitro β-cell dedifferentiation model using INS-1 cells to evaluate Op D’s influence on insulin secretion and dedifferentiation. Transcriptomic analysis was conducted to explore potential mechanisms by which Op D ameliorates dedifferentiation, with further validation via Western blotting and immunofluorescence. Flow cytometry, fluorescence microscopy, and related assays were used to assess Op D’s effects on oxidative stress. Endoplasmic reticulum (ER) tracing agents marked the ER, and laser confocal microscopy examined ER morphology, with ER stress inducers and inhibitors employed to clarify Op D’s mechanisms.ResultsResults indicated that Op D reduced blood glucose levels, improved glucose tolerance, enhanced insulin secretion, mitigated pancreatic atrophy, and increased PDX1 and FOXO1 expression levels. Furthermore, Op D inhibited ER stress, decreased GRP78 expression, reduced NGN3 levels, elevated PDX1, NKX6.1, and MAFA expression, and decreased oxidative stress-related products (ROS, MDA) while increasing SOD and GSH levels.DiscussionThese findings demonstrate that Op D can improve β-cell dedifferentiation by modulating the GRP78/ROS/PDX1 pathway to inhibit ER stress. |
| format | Article |
| id | doaj-art-e249eea7604a41e596941dbfead95313 |
| institution | Directory of Open Access Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| spelling | doaj-art-e249eea7604a41e596941dbfead953132025-08-20T03:53:42ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-04-011610.3389/fphar.2025.15632011563201Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathwayHaoxiang Sun0Ruixiang Tan1Yongzhi Sun2Yimeng Li3Ying Xie4Cheng Zhang5Jianping Song6Wei Zhu7Jiuyao Zhou8Changsheng Deng9Manxue Mei10Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaSci-Tech Industrial Park, Guangzhou University of Chinese Medicine, Guangzhou, ChinaDermatology Hospital of Southern Medical University, Guangzhou, ChinaThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, ChinaArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, ChinaArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, ChinaIntroductionThe incidence of diabetes is rising annually, significantly impacting public health and imposing a substantial economic burden on society. Ophiopogonin D (Op D) exhibits certain hypoglycemic effects; however, its mechanisms remain unclear.Methodsβ-cell dedifferentiation, distinct from β-cell apoptosis, is a pathogenic mechanism we aim to explore regarding Op D’s regulatory effects. We established an animal model of β-cell dedifferentiation to assess Op D’s impact on glucose tolerance, blood glucose levels, and insulin secretion. We employed immunohistochemistry and immunofluorescence to analyze the expression levels of dedifferentiation-related proteins. Additionally, we created an in vitro β-cell dedifferentiation model using INS-1 cells to evaluate Op D’s influence on insulin secretion and dedifferentiation. Transcriptomic analysis was conducted to explore potential mechanisms by which Op D ameliorates dedifferentiation, with further validation via Western blotting and immunofluorescence. Flow cytometry, fluorescence microscopy, and related assays were used to assess Op D’s effects on oxidative stress. Endoplasmic reticulum (ER) tracing agents marked the ER, and laser confocal microscopy examined ER morphology, with ER stress inducers and inhibitors employed to clarify Op D’s mechanisms.ResultsResults indicated that Op D reduced blood glucose levels, improved glucose tolerance, enhanced insulin secretion, mitigated pancreatic atrophy, and increased PDX1 and FOXO1 expression levels. Furthermore, Op D inhibited ER stress, decreased GRP78 expression, reduced NGN3 levels, elevated PDX1, NKX6.1, and MAFA expression, and decreased oxidative stress-related products (ROS, MDA) while increasing SOD and GSH levels.DiscussionThese findings demonstrate that Op D can improve β-cell dedifferentiation by modulating the GRP78/ROS/PDX1 pathway to inhibit ER stress.https://www.frontiersin.org/articles/10.3389/fphar.2025.1563201/fullophiopogonin DdedifferentiationdiabetesGRP78/ROS/PDX1unfolded protein response |
| spellingShingle | Haoxiang Sun Ruixiang Tan Yongzhi Sun Yimeng Li Ying Xie Cheng Zhang Jianping Song Wei Zhu Jiuyao Zhou Changsheng Deng Manxue Mei Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway ophiopogonin D dedifferentiation diabetes GRP78/ROS/PDX1 unfolded protein response |
| title | Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway |
| title_full | Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway |
| title_fullStr | Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway |
| title_full_unstemmed | Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway |
| title_short | Ophiopogonin D improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the GRP78/ROS/PDX1 signaling pathway |
| title_sort | ophiopogonin d improves pancreatic islet cell dedifferentiation to treat diabetes by regulating the grp78 ros pdx1 signaling pathway |
| topic | ophiopogonin D dedifferentiation diabetes GRP78/ROS/PDX1 unfolded protein response |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1563201/full |
| work_keys_str_mv | AT haoxiangsun ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT ruixiangtan ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT yongzhisun ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT yimengli ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT yingxie ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT chengzhang ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT jianpingsong ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT weizhu ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT jiuyaozhou ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT changshengdeng ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway AT manxuemei ophiopogonindimprovespancreaticisletcelldedifferentiationtotreatdiabetesbyregulatingthegrp78rospdx1signalingpathway |
